Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Cash from Operations (2020 - 2025)

Arcutis Biotherapeutics has reported Cash from Operations over the past 6 years, most recently at 26185000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 26185000.0 for Q4 2025, up 3600.67% from a year ago — trailing twelve months through Dec 2025 was 5625000.0 (up 94.98% YoY), and the annual figure for FY2025 was 5625000.0, up 94.98%.
  • Cash from Operations for Q4 2025 was 26185000.0 at Arcutis Biotherapeutics, up from 1754000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for ARQT hit a ceiling of 26185000.0 in Q4 2025 and a floor of 80344000.0 in Q1 2023.
  • Median Cash from Operations over the past 5 years was 44551500.0 (2023), compared with a mean of 39859100.0.
  • Biggest five-year swings in Cash from Operations: crashed 119.91% in 2021 and later surged 3600.67% in 2025.
  • Arcutis Biotherapeutics' Cash from Operations stood at 51709000.0 in 2021, then crashed by 37.43% to 71065000.0 in 2022, then grew by 20.86% to 56244000.0 in 2023, then surged by 98.67% to 748000.0 in 2024, then surged by 3600.67% to 26185000.0 in 2025.
  • The last three reported values for Cash from Operations were 26185000.0 (Q4 2025), 1754000.0 (Q3 2025), and 324000.0 (Q2 2025) per Business Quant data.